Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

387
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
387
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

78
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
78
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

3.3K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.3K
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

2.1K
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
2.1K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

86
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
86
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

433
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
433

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interindividual variability in metformin pharmacokinetics in pediatric patients.

Pediatric research·2026
Same author

Severe Thiopurine-Induced Myelosuppression in a Pediatric Acute Lymphoblastic Leukemia Patient With the NUDT15 *1/*6 Genotype: A Brief Report.

Clinical and translational science·2026
Same author

Development and Application of an LC-MS/MS Assay for Plasma Propofol Quantification in Major Noncardiac Surgical Patients to Evaluate Target-Controlled Infusion Algorithms.

Therapeutic drug monitoring·2026
Same author

Suicidal Ideation Effectiveness and Safety Outcomes from the Ketamine for Adult Depression Study (KADS).

Archives of suicide research : official journal of the International Academy for Suicide Research·2026
Same author

PharmVar GeneFocus: CYP1A2-Clinical Impact, Genetic Variation, and Updated Nomenclature.

Clinical pharmacology and therapeutics·2026
Same author

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5-HT<sub>3</sub> Receptor Antagonists: 2026 Update.

Clinical pharmacology and therapeutics·2026

Related Experiment Video

Updated: Nov 21, 2025

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.1K

PharmVar GeneFocus: CYP2B6.

Zeruesenay Desta1, Ahmed El-Boraie2, Li Gong3

  • 1Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Clinical Pharmacology and Therapeutics
|January 15, 2021
PubMed
Summary
This summary is machine-generated.

The Pharmacogene Variation Consortium (PharmVar) provides star (*) allele nomenclature for the CYP2B6 gene. This genetic variation affects how drugs like efavirenz and methadone are metabolized, impacting patient efficacy and safety.

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

986
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

19.7K

Related Experiment Videos

Last Updated: Nov 21, 2025

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.1K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

986
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

19.7K

Area of Science:

  • Pharmacogenomics
  • Human Genetics
  • Drug Metabolism

Background:

  • The human CYP2B6 gene is polymorphic, meaning it has variations within the population.
  • Genetic variations in CYP2B6 significantly influence the metabolism and bioactivation of various drugs.
  • Understanding these variations is crucial for optimizing drug efficacy and minimizing adverse events.

Purpose of the Study:

  • To provide a comprehensive overview of the CYP2B6 gene and its associated star (*) allele nomenclature.
  • To highlight the clinical significance of CYP2B6 genetic variations for key drugs.
  • To explain how PharmVar's haplotype information is integrated into PharmGKB and CPIC.

Main Methods:

  • Cataloging star (*) allele nomenclature for the CYP2B6 gene by the Pharmacogene Variation Consortium (PharmVar).
  • Reviewing scientific literature on CYP2B6 genetic variations and their impact on drug metabolism.
  • Describing the utilization of PharmVar haplotype data by PharmGKB and CPIC.

Main Results:

  • PharmVar maintains a standardized nomenclature for CYP2B6 genetic variants.
  • CYP2B6 variations affect the efficacy and safety of drugs including efavirenz, methadone, ketamine, and bupropion.
  • PharmGKB and CPIC leverage PharmVar data for clinical pharmacogenetics implementation.

Conclusions:

  • Accurate CYP2B6 allele nomenclature is essential for pharmacogenetic research and clinical practice.
  • Understanding CYP2B6 genotype-phenotype relationships improves patient outcomes for critical medications.
  • The integration of PharmVar data into PharmGKB and CPIC facilitates evidence-based prescribing guidelines.